Ontozry 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
PSUSA/10921
Periodic Safety Update EU Single assessment - 
09/11/2023 
12/01/2024 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202303 
cenobamate 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10921/202303. 
IA/0020/G 
This was an application for a group of variations. 
27/11/2023 
n/a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0019 
B.II.b.3.z - Change in the manufacturing process of 
31/07/2023 
n/a 
the finished or intermediate product - Other variation 
IB/0018 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
27/06/2023 
05/10/2023 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0016/G 
This was an application for a group of variations. 
13/06/2023 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
A.7 - Administrative change - Deletion of 
manufacturing sites 
PSUSA/10921
Periodic Safety Update EU Single assessment - 
14/04/2023 
n/a 
PRAC Recommendation - maintenance 
/202209 
cenobamate 
IB/0015 
B.II.b.3.z - Change in the manufacturing process of 
17/02/2023 
n/a 
the finished or intermediate product - Other variation 
IB/0014/G 
This was an application for a group of variations. 
17/02/2023 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of the AS 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
Page 3/6 
 
 
 
 
 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
PSUSA/10921
Periodic Safety Update EU Single assessment - 
27/10/2022 
n/a 
PRAC Recommendation - maintenance 
/202203 
cenobamate 
IA/0012 
B.I.a.2.a - Changes in the manufacturing process of 
22/09/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0011 
B.II.b.3.z - Change in the manufacturing process of 
26/07/2022 
n/a 
the finished or intermediate product - Other variation 
II/0009 
Update of section 5.3 of the SmPC in order to update 
07/07/2022 
05/10/2023 
SmPC 
information on toxicity to reproduction and 
development based on final results from nonclinical 
study “Effects of Cenobamate (YKP3089) on Embryo-
Fetal Development in Rats after Twice Daily Oral 
Administration”. 
The RMP version 3.0 has been agreed. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10921
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
cenobamate 
IAIN/0007/G 
This was an application for a group of variations. 
27/01/2022 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0005/G 
This was an application for a group of variations. 
05/01/2022 
n/a 
B.II.d.1.g - Change in the specification parameters 
and/or limits of the finished product - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter wit its 
corresponding test method as a result of a safety or 
quality issue 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IA/0006 
B.II.b.4.a - Change in the batch size (including batch 
15/12/2021 
n/a 
size ranges) of the finished product - Up to 10-fold 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
compared to the originally approved batch size 
T/0003 
Transfer of Marketing Authorisation 
11/10/2021 
28/10/2021 
SmPC, 
Labelling and 
PL 
IAIN/0002/G 
This was an application for a group of variations. 
07/07/2021 
28/10/2021 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0001 
A.1 - Administrative change - Change in the name 
12/05/2021 
28/10/2021 
SmPC, 
and/or address of the MAH 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
Labelling and 
PL 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
